Ferring Bravelle approved
Executive Summary
Ferring's Bravelle (urofollitropin) clears FDA May 6 for use in conjunction with human chorionic gonadotropin "for ovulation induction in patients who have previously received pituitary suppression." The intramuscular/subcutaneous injectable will be the third human-derived follitropin on the market, joining Serono's Fertinex (urofollitropin) and Pergonal (menotropins). Bravelle will be available in mid-May, Ferring said. The company has a pending NDA for use of Bravelle in in-vitro fertilization...